Brad Stanfield: Why Cancer Doctors Stood and Applauded

Key Takeaways

• Daraxonasib is a breakthrough drug targeting the RAS family of genes, including KRAS, which drives many cancers.
• In a trial, Daraxonasib doubled median survival time for metastatic pancreatic cancer patients compared to standard chemotherapy (13.2 months vs. 6.6 months).
• The drug works by clamping onto RAS proteins regardless of mutation type, making it effective against multiple cancer types, including pancreatic, colorectal, and lung cancers.
• Combining Daraxonasib with other therapies (e.g., targeting MTAP-loss tumors) shows promise in shrinking tumors and improving progression-free survival.
• This approach represents a major shift in cancer treatment, moving away from mutation-specific therapies to broadly targeting the RAS pathway.

Notable Quotes

“This trial shows that you can drug the active state of RAS itself, a proof of concept that this gene can finally be effectively targeted.”

Bottom Line

Stay informed about advancements in RAS-targeting therapies like Daraxonasib, as they hold transformative potential across multiple cancer types, especially for patients with limited treatment options.

Watch the Full Video